Breaking News, Promotions & Moves

Beacon Therapeutics Appoints New CEO and CFO

Lance Baldo, MD named Chief Executive Officer; Thomas Biancardi named Chief Financial Officer.

Author Image

By: Charlie Sternberg

Associate Editor

Beacon Therapeutics Holdings Limited, an ophthalmic gene therapy company, has appointed Lance Baldo, MD as Chief Executive Officer, effective August 12, 2024, and Thomas Biancardi as Chief Financial Officer, effective August 1, 2024. Lance Baldo, CEO Dr. Baldo brings more than 20 years of experience in biopharmaceuticals including the successful launch of two new indications and a new formulation for Lucentis while at Genentech. Most recently, he served as Chief Medical Officer at Fr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters